BostonGene AI framework identifies actionable targets in 65% of cancer of unknown primary cases at USCAP 2026
BostonGene presents multimodal AI CUP framework at USCAP 2026, identifying actionable targets in 65%+ of patients. Read the analysis.
Medical Devices & Diagnostics
Pharma & Biotech
Wilmington PharmaTech targets larger commercial API volumes with $50m Delaware expansion
Wilmington PharmaTech is investing $50 million to expand Delaware API capacity. Read why this could reshape U.S. small-molecule supply.
Pharma & Biotech
OverT Bio moves OVT-101 closer to clinic as solid tumour cell therapy race intensifies
OverT Bio is advancing OVT-101 toward the clinic in ovarian cancer. Read what its new advisory board could change for solid tumour cell therapy.
Medical Devices & Diagnostics
Photonova Spectra FDA clearance gives GE HealthCare a stronger hand in advanced CT imaging
GE HealthCare’s Photonova Spectra just won FDA clearance. Find out what this means for photon-counting CT, imaging workflows, and hospital adoption.
Pharma & Biotech
Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate
MaaT Pharma’s MaaT013 posted pivotal Phase 3 GI-aGvHD data. Read what it could mean for EMA approval, adoption, and microbiome therapeutics.
Pharma & Biotech
Sesh Products clears PMTA filing threshold as FDA substantive review begins
Sesh Products' 64-SKU nicotine pouch PMTA enters FDA substantive scientific review. Analysis of what this means for independent pouch brands. Read more.
Pharma & Biotech
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
Pharma & Biotech
What Celosia Therapeutics’ Phase 1b CTx1000 trial could reveal about TDP-43 targeting in ALS
Celosia Therapeutics has dosed the first ALS patient with CTx1000. Read why this TDP-43 gene therapy trial could reshape the ALS pipeline.
Pharma & Biotech
Extended-interval nAMD therapy gets a new contender as Innovent Biologics posts Phase 3 STAR data
Innovent Biologics’ efdamrofusp alfa cleared a key Phase 3 nAMD hurdle in China. Read what the STAR data could change for retinal treatment.
Pharma & Biotech
Can Prestige Biopharma turn HD204 Phase 3 data into a credible Avastin biosimilar launch?
Prestige Biopharma reported positive HD204 Phase 3 data in NSCLC. Read what the bevacizumab biosimilar result could change next.